These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31624102)

  • 21. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors.
    Gulde S; Wiedemann T; Schillmaier M; Valença I; Lupp A; Steiger K; Yen HY; Bäuerle S; Notni J; Luque R; Schmid H; Schulz S; Ankerst DP; Schilling F; Pellegata NS
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
    Peverelli E; Olgiati L; Locatelli M; Magni P; Fustini MF; Frank G; Mantovani G; Beck-Peccoz P; Spada A; Lania A
    Cancer Lett; 2010 Feb; 288(2):170-6. PubMed ID: 19619936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
    Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
    Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
    Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
    Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features.
    Flores-Martinez Á; Venegas-Moreno E; Dios E; Remón-Ruiz P; Gros-Herguido N; Vázquez-Borrego MC; Madrazo-Atutxa A; Japón MA; Kaen A; Cárdenas-Valdepeñas E; Roldán F; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32971845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
    Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
    Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
    Reubi JC; Schonbrunn A
    Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.
    Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ
    Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
    Günther T; Culler M; Schulz S
    Mol Endocrinol; 2016 Apr; 30(4):479-90. PubMed ID: 26967369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
    Di Muro G; Catalano R; Treppiedi D; Barbieri AM; Mangili F; Marra G; Di Bari S; Esposito E; Nozza E; Lania AG; Ferrante E; Locatelli M; Modena D; Steinkuhler C; Peverelli E; Mantovani G
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug design at peptide receptors: somatostatin receptor ligands.
    Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
    J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.